Compare Twist Bioscience Corp (TWST) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Twist Bioscience Corp trades at $88.31 (market cap $5.45B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.54. The key difference: Twist Bioscience Corp is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| TWST | VCIT | |
|---|---|---|
Market Cap | $5.45B | — |
Sector | Health | Fixed Income |
52-Week High | $102.88 | $84.82 |
52-Week Low | $24.16 | $81.45 |
Enterprise Value | $5.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TWST trades at $95.86, up 2.14% today, with a bullish technical signal and strong institutional interest. Revenue growth is robust, rising from $204M in 2022 to $377M in 2025, though the company remains unprofitable with a net income margin of -19.85%. Recent news highlights AI-driven collaborations and earnings beats, but cash flow trends show persistent operational losses.
The outlook is mixed; analyst consensus is bullish with a $91.63 price target, but profitability challenges and negative cash flows pose significant risks. Investment opportunity lies in continued revenue expansion and AI partnerships, while execution risks and high valuations require caution.
VCIT trades at $81.71, down 0.28% on the day, with a bearish technical signal driven by moving averages. The fund provides exposure to intermediate-term corporate bonds, offering a competitive yield and low expense ratio. Recent news highlights its role in fixed-income portfolios, comparing favorably on cost and income potential against peers like iShares alternatives.
Outlook remains cautious near-term due to technical weakness, but the fund's low-cost structure and steady dividends appeal for income-focused investors. Risks include interest rate sensitivity and corporate credit conditions, requiring monitoring of economic indicators for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
